Literature DB >> 10331603

Single-strand conformation polymorphism analysis in the FMR1 gene.

S Castellví-Bel1, A Sánchez, C Badenas, J Mallolas, A Barceló, D Jiménez, M Villa, X Estivill, M Milà.   

Abstract

The fragile X syndrome is due to an expansion of the CGG trinucleotide repeat in the FMR1 gene and hypermethylation of its 5' upstream CpG island in about 95% of the cases. The remaining 5% of cases correspond to other molecular alterations in FMR1 gene such as partial or complete deletions, or point mutations within the coding sequence. We selected 31 patients with clinical manifestations of fragile X syndrome, scoring 16 or more in Hagerman's checklist, but without the CGG expansion. We performed single-strand conformation polymorphism analysis using a nonradioactive technique (silver staining) and we detected six anomalous migrations that, by sequence analysis, corresponded to six nucleotide changes. We screened two different populations (control and fragile X) for these changes, and concluded that they correspond to five new polymorphisms within the FMR1 gene and to one possible synonymous mutation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331603

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  3 in total

1.  A nonsense mutation in FMR1 causing fragile X syndrome.

Authors:  Karen Grønskov; Karen Brøndum-Nielsen; Alma Dedic; Helle Hjalgrim
Journal:  Eur J Hum Genet       Date:  2011-01-26       Impact factor: 4.246

2.  Identification of novel FMR1 variants by massively parallel sequencing in developmentally delayed males.

Authors:  Stephen C Collins; Steven M Bray; Joshua A Suhl; David J Cutler; Bradford Coffee; Michael E Zwick; Stephen T Warren
Journal:  Am J Med Genet A       Date:  2010-10       Impact factor: 2.802

3.  Array-based FMR1 sequencing and deletion analysis in patients with a fragile X syndrome-like phenotype.

Authors:  Stephen C Collins; Brad Coffee; Paul J Benke; Elizabeth Berry-Kravis; Fred Gilbert; Ben Oostra; Dicky Halley; Michael E Zwick; David J Cutler; Stephen T Warren
Journal:  PLoS One       Date:  2010-03-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.